872.14
-12.55
(-1.42%)
As of February 5 at 1:20:57 PM CST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 16 | 16 |
| Avg. Estimate | 366.48M | 360.83M | 1.48B | 1.63B |
| Low Estimate | 353.5M | 356.5M | 1.46B | 1.61B |
| High Estimate | 372.87M | 368.2M | 1.49B | 1.66B |
| Year Ago Sales | 337.76M | 330.34M | 1.35B | 1.48B |
| Sales Growth (year/est) | 8.50% | 9.23% | 9.29% | 10.47% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| BSY.MX | -- | -- | -- | -- |
| S&P 500 | 6.52% | 6.29% | 9.55% | 14.25% |
Upgrades & Downgrades
| Maintains | JP Morgan: Neutral to Neutral | 4/9/2025 |
| Initiated | UBS: Neutral | 3/31/2025 |
| Downgrade | Goldman Sachs: Neutral to Sell | 2/28/2025 |
| Maintains | Baird: Outperform to Outperform | 2/27/2025 |
| Maintains | Rosenblatt: Buy to Buy | 2/27/2025 |
| Maintains | Rosenblatt: Buy to Buy | 2/25/2025 |